World Health Organization Regional Office for South-East Asia

 

 

 

 

 

 

 

 

 

Public Information & Events

 

Press Releases

 

Press Releases

 

 

SEA/PR/1487

Unified action: The only way forward to control TB

New Delhi 23 March: Progress in reducing the number of tuberculosis (TB) cases stands at a crossroads today. While over 87% of the two million TB patients in the South-East Asia Region are being treated successfully every year, multidrug drug resistant TB (MDR-TB) and HIV-associated TB pose a serious threat to the gains achieved so far.

“We simply must stop TB. This succinct but compelling message implies a shared responsibility for unified action at all levels, by health-care providers, national and international partners and communities to control and eliminate TB”,  said Dr. Samlee Plianbangchang, WHO’s Regional Director for South-East Asia.

Annually over 10% of the estimated 3.6 million people living with HIV (PLHIV) in the Region are likely to develop active TB. Hence, it is critical that both HIV/AIDS and TB control programmes ensure that the benefits of expanding access to HIV counselling, testing and care, including access to antiretroviral therapy (ART), reach TB patients who also have HIV.

Levels of drug-resistance in TB patients in most parts of the Region are still low at less than 3%, due to good implementation of basic DOTS. However, given the large number of TB patients, this represents over 150 000 new patients with MDR-TB every year. “Widespread unregulated use of anti-TB drugs outside of national programmes is our major concern in the context of drug resistant TB,” stressed Dr Plianbangchang.

Increasing investments in health-care systems are essential to ensuring that all TB patients have equitable access to free and quality care at all health care facilities at the primary level. What is also urgently required is that all health professionals, from both the public and private sectors, adhere strictly to internationally recommended standards for TB care, and that appropriate measures are duly implemented to contain unregulated use of anti-TB drugs to prevent the emergence of drug resistance. 

For more information please contact: Ms Vismita Gupta-Smith, Public Information and Advocacy Officer, WHO South-East Asian Regional Office (SEARO), New Delhi, Tel: 91-11-23309401, e-mail: guptasmithv@searo.who.int or Ms Shima Roy Communication Officer at telephone: 011 2330 9591; e-mail roys@searo.who.int 

 

All press releases, fact sheets and other WHO media material may be found at: www.searo.who.int.

.###

Back

 

||| | ||